Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Lenvatinib - Eisai Co Ltd

Drug Profile

Lenvatinib - Eisai Co Ltd

Alternative Names: E-7080; ER-203492-00; Kisplyx; Lenvatinib mesylate; LENVIMA; Lenvima; MK-7902

Latest Information Update: 12 Nov 2019

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Eisai Co Ltd
  • Developer Eisai Co Ltd; Merck & Co; Merck Sharp & Dohme; MSD KK; National Cancer Center (Tokyo); National University Hospital (Singapore); Ono Pharmaceutical; SFJ Pharmaceuticals
  • Class Amides; Antineoplastics; Chlorobenzenes; Cyclopropanes; Phenyl ethers; Quinolines; Small molecules; Urea compounds
  • Mechanism of Action Platelet derived growth factor alpha receptor antagonists; Proto oncogene protein c ret inhibitors; Proto oncogene protein c-kit inhibitors; Type 1 fibroblast growth factor receptor antagonists; Type 3 fibroblast growth factor receptor antagonists; Type 4 fibroblast growth factor receptor antagonists; Type-2 fibroblast growth factor receptor antagonists; Vascular endothelial growth factor receptor 3 antagonists; Vascular endothelial growth factor receptor-1 antagonists; Vascular endothelial growth factor receptor-2 antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Thyroid cancer; Liver cancer; Malignant melanoma
  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Liver cancer; Renal cell carcinoma; Thyroid cancer
  • Registered Endometrial cancer
  • Phase III Malignant melanoma; Non-small cell lung cancer; Urogenital cancer
  • Phase II Biliary cancer; Colorectal cancer; Gastric cancer; Neuroendocrine tumours; Solid tumours; Thymoma
  • Phase I/II Breast cancer
  • Phase I Ovarian cancer
  • Discontinued Cancer; Glioma; Lymphoma

Most Recent Events

  • 06 Nov 2019 Eisai plans a phase II trial for Osteosarcoma (Second-line therapy or greater, Combination therapy, In children, In adolescents, In adults) (PO) in February 2020 (NCT04154189)
  • 04 Oct 2019 Final efficacy data from a phase Ib/II KEYNOTE-146/Study 111 trial in Endometrial cancer released by Merck and Eisai
  • 30 Sep 2019 Final efficacy and adverse events data from a phase Ib/II KEYNOTE-146 trial in Endometrial cancer released by Merck
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top